SAI Life Sciences is an innovator focused CRDMO in small molecule (NCE) space. The company is a fully integrated CRDMO player with presence in both discovery as well as development and commercial manufacturing. CRO and CDMO account for 37% and 63% of the revenue, with about 30 molecules in the commercial manufacturing stage. SAI has four manufacturing facilities two in India and one each in the UK (Manchester) and the US (Boston), serving 18 out of the 25 largest global pharmaceutical companies. The company has a healthy pipeline with 6 molecules (three potential blockbusters) in Phase III/Registration stage and over 40 programs advanced to IND or various clinical trial stages.
| CMP (Rs) | ₹861 |
| Target (Rs) | ₹1,055 |
| Upside | 22% |
| Bloomberg Code | SAILIFE IN |
| Curr Shares O/S (mn)* | 209.8 |
| Mkt Cap (Rsbn/USDmn) | 180.7/2038 |
| 52 Wk H / L (Rs)* | 943/636 |
| 5 Year H / L (Rs)* | 943/636 |
| Daily Vol. 3M Avg. (‘000) | 1569.9 |
Source: ACE Equity, MNCL Research
| % | 1M | 6M | 1Yr |
|---|---|---|---|
| SAILIFE | 0.0 | 34.6 | N/A |
| NIFTY | 1.3 | 12.9 | 1.1 |
Source: ACE Equity, MNCL Research
| % | Jun-25 | Mar-25 | Dec-24 |
|---|---|---|---|
| Promoter | 35.2 | 35.2 | 35.2 |
| Inst./Govt. | 36.2 | 25.6 | 23.7 |
| Others | 28.6 | 39.2 | 41.1 |
Source: ACE Equity, MNCL Research
With low cost and rising technical know-how, Indian CRDMOs has witnessed increasing demand from the global Pharma companies. Indian CRDMO has grown at a CAGR of 12.6% over the past five years. Efforts to de-risk the supply chain (post Covid) by the global pharma companies and the proposed Bio-secure Act in US, will further act as a tailwind for the Indian CRDMO sector. Indian CRDMO industry, largely dominated by small molecules, is expected to grow at CAGR of 14% over FY23-28.
SAI Life follows a differentiated global delivery model – with discovery and development laboratories near key innovation hubs in the US and UK, and large-scale R&D and manufacturing facilities in India. Out of the total employee strength of ~3400 in FY25, 2605 are scientists. The company has further on-boarded 250 scientists and technical professionals in Q1FY26. With increasing focus on Biologics, it launched state-of-the-art Biologics facility at its Hyderabad campus and has started building a new Process R&D block, which will nearly double its Process R&D capabilities. It is also adding clinical-scale peptide capabilities, as well as early-phase formulation capabilities.
After creating a niche in the innovator focussed CRDMO for the small molecules (NCEs or New Chemical Entities), SAI is focussing now on the fast-emerging Biologics space. NBEs or New Biological Entities are large complex biological entities derived from living organisms. Biologics have revolutionized treatment for many serious ailments like Autoimmune diseases, Cancer (Targeted therapies like ADC or Anti-Body Drug Conjugates that attack cancer cells without harming healthy ones) Diabetes, Rare genetic disorders (Gene and enzyme replacement therapies), Infectious diseases etc. CRDMO for Biologics and Bio-similar molecules are expected to grow at a CAGR of 17.8% over the next five years, against 13.7% CAGR of growth in the small molecule CRDMO over the same period (Source: Frost & Sullivan Report). The company is strengthening its capabilities in the new modalities like ADCs, Oligonucleotides, mRNA Therapeutics and Peptides. New modalities have already started contributing to the revenue and it accounted for 7% of the revenue in FY25.
SAI Life is one of the very few fully integrated innovator focused CRDMO player, with a niche in the small molecule. The company has strong R&D capabilities and is strengthening its capabilities in the high growth Biologics CRDMO. Our 1 Yr forward DCF based Target price for SAI Life stands at Rs1055, with a potential upside of 22% from the current levels.
| Y/E Mar (Rs mn) | FY24 | FY25 | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Sales | 14,652 | 16,946 | 19,996 | 24,355 | 29,177 |
| YoY (%) | 20.4 | 15.7 | 18.0 | 21.8 | 19.8 |
| EBIDTA | 2,871 | 4,078 | 5,098 | 6,367 | 7,687 |
| YoY (%) | 70.0 | 42.0 | 25.0 | 24.9 | 20.7 |
| PAT | 828 | 1,701 | 2,417 | 3,345 | 4,072 |
| YoY (%) | 729.0 | 105.5 | 42.0 | 38.4 | 21.7 |
| EPS (Rs) | 4.6 | 8.2 | 11.6 | 16.0 | 19.5 |
| Y/E Mar | FY24 | FY25 | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| EBIDTAM (%) | 19.6 | 24.1 | 25.5 | 26.1 | 26.3 |
| NPM (%) | 5.7 | 10.0 | 12.1 | 13.7 | 14.0 |
| PER (x) | 166.7 | 93.2 | 74.2 | 53.6 | 44.0 |
| EV/ EBITDA (x) | 49.8 | 38.1 | 34.9 | 27.6 | 22.5 |
| RoE (%) | 8.5 | 8.0 | 10.7 | 13.1 | 13.9 |
| RoIC (%) | 7.6 | 10.0 | 11.3 | 11.6 | 13.4 |
| Pre-Tax OCF/EBITDA (%) | 96.5 | 82.3 | 157.1 | 88.0 | 88.9 |
Source: Company Sai Life Sciences Ltd, MNCL Research
| Stock Details | Industry | Buying Range (₹) | CMP* (₹) | Target Price (₹) | Upside Potential % |
|---|---|---|---|---|---|
| Bharat Electronics Ltd | Defence | 407-420 | 414 | 463 | 12% |
| Brigade Enterprises Ltd | Real-estate | 920-970 | 943 | 1341 | 42% |
| Clean Science & Technology Ltd | Specialty Chemical | 1045-1100 | 1072 | 1220 | 14% |
| Elecon Engineering Company Ltd | Capital Goods | 540-580 | 557 | 733 | 32% |
| ICICI Bank Ltd | BFSI | 1360-1400 | 1380 | 1700 | 23% |
| National Aluminium Company Ltd | Metals | 215-235 | 224 | 280 | 25% |
| Sai Life Sciences Ltd | Healthcare | 840-885 | 861 | 1055 | 22% |
| TBO Tek Ltd | Hospitality | 1520-1600 | 1562 | 1853 | 19% |
| TCPL Packaging Ltd | Packaging | 3300-3500 | 3402 | 4303 | 26% |
| Vesuvius India Ltd | Metals | 490-520 | 505 | 585 | 16% |
| Windlas Biotech Ltd | Healthcare | 890-940 | 915 | 1225 | 34% |
*Closing Price as on 10-10-2025
Make this Diwali truly rewarding – Open your MNCL Demat Account today!
Disclaimer - Investments in securities market are subject to market risk, read all the related document carefully before investing.
https://www.mnclgroup.com/
Empower your finances with ReSach – the stock trading apptrusted by serious investors. Whether you're planning to invest in stocks, explore commodity trading, or need a financial advisor to guide you, Resach brings it all under one platform.
Start trading today with ReSach and unlock seamless investing on the go.
Name of the Company has changed from Networth Stock Broking Limited to Monarch Networth Capital Limited upon Certification of Incorporation received from Registrar of Companies, Mumbai vide certificate dated 13th October, 2015.
If you are not satisfied with the resolution provided, you can lodge your complaint online at: https://scores.sebi.gov.in/link
In case of grievance client can log on to the SMART ODR Portal, if they are unsatisfied with the response provided by us. Your attention is drawn to the SEBI circular no. SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/131 dated July 31, 2023, on “Online Resolution of Disputes in the Indian Securities Market”.
Purchase of REs only gives buyer the right to participate in the ongoing Rights Issue of the concerned company by making an application with requisite application money or renounce the REs before the issue closes. REs which are neither subscribed by making an application with requisite application money nor renounced, on or before the Issue closing date shall lapse and shall be extinguished after the Issue closing date. Please check your dp account for further details.
Please do not share your online trading password with anyone as this could weaken the security of your account and lead to unauthorized trades or losses.
Monarch Networth Capital Limited (‘MNCL’) | CIN No.: L64990GJ1993PLC120014
Unit No. 803-804A, 8th Floor, X-Change Plaza, Block No. 53, Zone 5, Road-5E, Gift City, Gandhinagar - 382050, Gujarat
Ahmedabad
“Monarch House”, Opp Prahladbhai Patel garden, Near Ishwar Bhuvan, Commerce Six Roads, Navrangpura, Ahmedabad - 380009
Mumbai
Monarch Networth Capital Limited, G Block, Laxmi Tower, B Wing, 4th Floor, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
Email for Grievance: grievances@mnclgroup.com
Investors are requested to note that Stock broker (Monarch Networth Capital Ltd) is permitted to receive money from investors through designated bank accounts only named as Up streaming Client Nodal Bank Account (USCNBA). Stock broker (Monarch Networth Capital Ltd) is also required to disclose these USCNB accounts to Stock Exchange. Hence, you are requested to use following USCNB accounts only (Click to View) for the purpose of dealings in your trading account with us. The details of these USCNB accounts are also displayed by Stock Exchanges on their website under “Know/ Locate your Stock Broker".
Mechanism for addressing grievances and information about SCORES.
Mechanism for addressing grievances and information about SCORES.
Monarch Networth Capital Limited (‘MNCL’) | CIN No.: L64990GJ1993PLC120014
(As per LODR Regulations and Companies Act, 2013)
Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances : Mr. Nitesh Tanwar
Monarch Networth Capital Limited
Unit No. 803-804A, 8th Floor, X-Change Plaza, Block No. 53, Zone 5, Road-5E, Gift City, Gandhinagar - 382050, Gujarat
Ahmedabad
“Monarch House”, Opp Prahladbhai Patel garden, Near Ishwar Bhuvan, Commerce Six Roads, Navrangpura, Ahmedabad – 380009
Mumbai
Monarch Networth Capital Limited, G Block, Laxmi Tower, B Wing, 4th Floor, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
Phone: 022 - 66476400 / 66476405
Email: cs@mnclgroup.com
Email for Grievance: cs@mnclgroup.com
Listing of Equity Shares on Stock Exchange at
BSE
NSE
(Formerly known as Link Intime India Private Limited)
For any queries related to broking please contact helpdesk@mnclgroup.com.
‘Investments in securities market are subject to market risks, read all the related documents carefully before investing.’
